Isofol Medical AB (publ) (ISOFOL.ST) Research
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Market snapshot
- Symbol
- ISOFOL.ST
- Price
- $0.68
- Day change
- +0.15%
- Market cap
- $216.7M
- P/E ratio
- -2.77x
- 52-week range
- 0.5515-1.18
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Peer companies
- Alzinova AB (publ) (ALZ.ST)
- Annexin Pharmaceuticals AB (publ) (ANNX.ST)
- Bio-Works Technologies AB (publ) (BIOWKS.ST)
- Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
- Enorama Pharma AB (publ) (ERMA.ST)
- Initiator Pharma A/S (INIT.ST)
- IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
- Karolinska Development AB (publ) (KDEV.ST)
Open Isofol Medical AB (publ) (ISOFOL.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.